Objective: Gray matter (GM) damage and meningeal inflammation have been associated with early disease onset and a more aggressive disease course in multiple sclerosis (MS), but can these changes be identified in the patient early in the disease course? Methods: To identify possible biomarkers linking meningeal inflammation, GM damage, and disease severity, gene and protein expression were analyzed in meninges and cerebrospinal fluid (CSF) from 27 postmortem secondary progressive MS and 14 control cases. Combined cytokine/chemokine CSF profiling and 3T magnetic resonance imaging (MRI) were performed at diagnosis in 2 independent cohorts of MS patients (35 and 38 subjects) and in 26 non-MS patients. Results: Increased expression of proinflammatory cytokines (IFNc, TNF, IL2, and IL22) and molecules related to sustained B-cell activity and lymphoid-neogenesis (CXCL13, CXCL10, LTa, IL6, and IL10) was detected in the meninges and CSF of postmortem MS cases with high levels of meningeal inflammation and GM demyelination. Similar proinflammatory patterns, including increased levels of CXCL13, TNF, IFNc, CXCL12, IL6, IL8, and IL10, together with high levels of BAFF, APRIL, LIGHT, TWEAK, sTNFR1, sCD163, MMP2, and pentraxin III, were detected in the CSF of MS patients with higher levels of GM damage at diagnosis. Interpretation: A common pattern of intrathecal (meninges and CSF) inflammatory profile strongly correlates with increased cortical pathology, both at the time of diagnosis and at death. These results suggest a role for detailed CSF analysis combined with MRI as a prognostic marker for more aggressive MS. ANN NEUROL 2018;83:739-755 D isability progression in multiple sclerosis (MS) patients is accompanied by the accumulation of chronic white matter (WM) demyelination with limited repair, axonal loss, diffuse inflammatory changes in the normal-appearing WM, 1,2 and both focal and diffuse cortical gray matter (GM) demyelination and View this article online at wileyonlinelibrary.com.
D
isability progression in multiple sclerosis (MS) patients is accompanied by the accumulation of chronic white matter (WM) demyelination with limited repair, axonal loss, diffuse inflammatory changes in the normal-appearing WM, 1,2 and both focal and diffuse cortical gray matter (GM) demyelination and neurodegeneration. [3] [4] [5] [6] Neuroimaging has confirmed that cortical lesions and GM atrophy are strongly related to physical disability [7] [8] [9] and that these are present from the earliest stages of the disease, 4, 10, 11 suggesting that leptomeningeal immune cell infiltration and compartmentalized inflammation within the subarachnoid space may play a key role in the pathogenesis of this cortical pathology. 5, [11] [12] [13] [14] [15] Increased meningeal inflammation is associated with a gradient of neuronal, astrocyte, and oligodendrocyte damage and with microglial activation, which was higher in the superficial cortical layers (I-III). 5, 16 A strong association between meningeal inflammation and the severity of underlying pathology is also seen in the spinal cord and cerebellum in primary progressive MS and in the brain biopsies of patients with a recent diagnosis of MS. 11, [17] [18] [19] Early in vivo detection of cortical pathology is vital to be able to effectively target the underlying mechanisms of progressive disease before significant disability develops. Cortical pathology could potentially be a biomarker indicating underlying compartmentalized inflammation. However, the in vivo detection of cortical lesions using magnetic resonance imaging (MRI) is still suboptimal 20, 21 despite several improvements including the introduction of GM-specific pulse sequences 8, 20, [22] [23] [24] at high-field 3T and ultra-high-field 7T MRI. 25, 26 Therefore, there is a need for additional surrogate biomarkers of cortical GM demyelination and neurodegeneration and compartmentalized meningeal inflammation to identify early in the disease course those individuals at risk of a more severe disease course. Several fluid biomarker studies have revealed the differential expression of individual cerebrospinal fluid (CSF) proteins in MS compared to controls. The presence of high levels of the neurofilament light-chain protein is associated with a higher risk of conversion to clinically definite MS and/or increased brain and spinal cord atrophy. 27 Increased levels of proinflammatory cytokines and chemokines such as CXCL13, 28 CXCL12, 28 TNF, 29, 30 and IFNc 31 are detected in the CSF of MS patients. However, an association between the presence of these or other inflammatory mediators in the CSF, and increased GM pathology and clinical outcomes has not yet been shown. Our previous studies using postmortem analysis of paired CSF and meningeal samples, obtained from MS cases with or without meningeal lymphoid like tissues, 12 has suggested that increased TNF and IFNc expression is associated with more severe cortical pathology.
Here, we undertook a systematic and more comprehensive analysis of inflammatory and cytotoxic molecules expressed in the meninges and CSF derived from 27 postmortem secondary progressive MS (SPMS) subjects, stratified according to the level of meningeal inflammation and cortical demyelination, and 14 controls. This was then compared with the profile of inflammationrelated molecules in diagnostic CSF in 2 independent cohorts of patients with MS, stratified by the presence of low or high numbers of cortical lesions determined by 3-dimensional (3D) double inversion recovery (DIR) MRI imaging, a training set (TS; 35 subjects) and a validation set (VS; 38 subjects), with the overall aim of determining whether cytokine profiles indicating greater cortical damage and a more rapidly progressive disease course could also be found in newly diagnosed MS patients.
Materials and Methods

Study Populations and Subgroup Classification
POSTMORTEM MS AND CONTROL COHORT. Snap frozen tissue blocks from 27 SPMS and 14 non-MS control (without any evidence of neuropathology) postmortem brains (Table 1) were obtained from the U.K. MS Society Tissue Bank at Imperial College (ethical approval: National Research Ethics Committee, 08/MRE09/31). Three snap frozen cortical tissue blocks (2 3 2 3 1cm), representative of different regions of the frontal and temporal cortex, were examined from every SPMS case and were screened for the presence and extent of GM demyelination and the degree of meningeal inflammation. 6, 16, 32 Fifteen SPMS cases were classified by a low level of meningeal inflammation and demyelination (PM-MSlow) and 12 by a high level of meningeal inflammation and demyelination (PM-MShigh), as previously described. 6 The degree of meningeal inflammation was assessed by manually counting the number of hematoxylinstained cell nuclei in 2 meningeal infiltrates for each examined tissue block (Fig 1A) . The presence and extent of subpial (type III) GM demyelination was then assessed in all tissue blocks using immunohistochemistry for myelin oligodendrocyte glycoprotein and the percentage of demyelinated GM with respect to the total GM was calculated (see Fig 1B) following the procedures previously optimized. 16 Not all MS and control cases from which the meningeal RNA had been prepared also had a paired CSF sample available. Therefore, for the CSF analysis, we included further samples from cases of SPMS for which the degree of inflammation and demyelination had been assessed in the same way (for details, see Table 1 ).
MS PATIENT COHORTS. Seventy-eight consecutive treatmentnaive relapsing-remitting MS (RRMS) patients from he MS Center of Verona University Hospital (Italy) were screened at diagnosis between September 2014 and February 2015. A first TS cohort comprising 35 RRMS patients was enrolled. Inclusion criteria were the presence of at least 10 cortical lesions or < 2 cortical lesions, which permitted the stratification of the cohort into 2 subsets (TS-MShigh and TS-MSlow). Forty-three patients were excluded as that they did not meet the inclusion criteria. A second independent group of 38 treatment-naive MS patients (Table 2 ) from the MS Center of Verona University Hospital (29 patients) and the MS Center of Montichiari (9 patients) were consecutively recruited (March 2015 to August 2015) at diagnosis without any bias with respect to the GM and WM lesion load and were termed the VS. They were age and sex matched with the TS group. Each patient was then assigned to a low (VS-MSlow) or high (VS-MShigh) group based on whether their cortical lesion count was above or below the median number of 7 cortical lesions for the whole cohort (see Table 2 ).
All the MS patients had a confirmed diagnosis of MS 33 and underwent neurological evaluation, 3T MRI, and CSF examination. Twelve subjects with noninflammatory neurological diseases (NIND; including 3 with cerebrovascular disease, 3 degenerative disease, 2 periphery neuropathies, 2 headache/dizziness without any central nervous system [CNS] abnormality, and 2 ischemic white matter lesions) and 14 subjects with other inflammatory neurological diseases (OIND; including 3 with immunemediated encephalitis, 2 neuromyelitis optica, 2 neurosarcoidosis, 2 leukoencephalopathies, 2 CNS paraneoplastic syndrome, 2 CNS vasculitis, 1 Behcet disease) were also recruited at the time of the diagnosis. They also underwent neurological evaluation, 3T MRI, and CSF examination.
The local ethics committee approved the study. Informed consent was obtained from the patients.
Postmortem Study
MENINGEAL DISSECTION AND GENE EXPRESSION ANALY-SIS. Meningeal tissues closely adjacent to the areas of either subpial cortical demyelination or normal-appearing GM were dissected from snap frozen tissue blocks from 20 SPMS and 10 controls (see Table 1 ), as previously described. 5, 12 To obtain a sufficient amount of RNA for gene expression analysis, the RNA obtained from 3 tissue blocks per case was pooled. RNA extractions were performed using the RNeasy Lipid Tissue Midi Kit (Qiagen, Valencia, CA), following procedures previously optimized for use with human tissues. 34 The RNA concentration and quality were determined using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), respectively. Gene expression analysis of 84 human cytokines and chemokines was performed using a Qiagen RT Profile array (Human Cytokines & Chemokines RT2 Profiler PCR Array, cat. no. PAHS-150Z), following the manufacturer's instructions, including the preamplification step (12 cycles of 15 seconds at 95 8C and 2 minutes at 60 8C). All samples were run in triplicate, and the results were analyzed by 2 independent operators (R.M. and C.C.).
POSTMORTEM CSF PROTEIN ANALYSIS. The protein levels of 30 inflammatory cytokines and chemokines (V-PLEX Plus Human Cytokine 30-Plex kit; Meso Scale Diagnostics, Rockville, MD) were determined in the postmortem CSF obtained at autopsy from 20 SPMS (10 PM-MShigh and 10 PM-MSlow meningeal inflammation; see Table 2 ) and 10 healthy controls using the Meso Scale Discovery (MSD) electrochemiluminescence system (Supplementary Table 1 ). The MSD detection system was used with the manufacturer's protocol and provided a combination of high sensitivity with low background and a 5 log order of magnitude dynamic range.
Clinical Study
PATIENT CSF PROTEIN ANALYSIS. CSF samples were obtained at least 2 months after the last relapse and within 1 week of the MRI, according to Consensus Guidelines for CSF and Blood Biobanking. 35 After centrifugation, the supernatant and the cell pellet were stored separately at 280 8C until use. Immunoglobulin G (IgG) index and presence/ absence of oligoclonal bands for each MS patient are reported in Table 2 . The CSF analysis was optimized and performed by 2 independent investigators (R.M. and S.Ro.), blinded with respect to the clinical and MRI features. The levels of neurofilament protein light chain (NF-L) in CSF were measured using the Human NF-light ELISA kit (MyBioSource, San Diego, CA) according to the manufacturer's instructions, and the quantification was carried out on a VICTOR X3 2030 Multilabel Plate Reader (Perkin Elmer, Walluf, Germany). Intraassay variability (coefficients of variation) of the samples was <10%.
The levels of 69 inflammatory mediators (Supplementary  Table 2) were assessed using a combination of immune-assay multiplex techniques based on the Luminex technology (40-and 37-Plex, Bio-Plex X200 System equipped with a magnetic workstation; BioRad, Hercules, CA). All samples were run in duplicate in the same experiment and in 2 consecutive experiments, to verify the reproducibility and consistency of the results. The CSF level of each protein detected during the analysis was normalized to the total protein concentration of each CSF sample (measured by Bradford protocol). When comparing the 2 groups of 14 NIND and 12 OIND controls, no differences were revealed in the presence and levels of the examined molecules. Therefore, the 2 groups were included as a single control group.
MRI ACQUISITION PROTOCOL. Three-tesla MRI was performed on each patient at least 2 months from the last relapse, at the Radiology Unit of the University Hospital of Verona (Borgo Trento). MRI sequences were acquired using an Achieva 3T MR Scanner (Philips, Best, the Netherlands). The following image sets were acquired: Step B: Cortical Lesion Number and Volume. The number of cortical lesions was assessed on DIR images following the recent recommendations for cortical lesions scoring in patients with MS. 36 This number included both intracortical and mixed (WM/GM) lesions. To be as specific as possible, we have also calculated the number of intracortical lesions alone. The total cortical lesion volume and the volume of intracortical lesions were calculated using a semiautomatic thresholding technique based on a Fuzzy C-mean algorithm 37 included in software developed at the National Institutes of Health, Medical Images Processing, Analysis, and Visualization (http:// mipav.cit.nih.gov).
Step C: Cortical Thickness Evaluation. The estimation of the cortical thickness was performed using the 3D T1 TFE sequence, the automated, volume-based Advanced Normalization Tools (ANTs), 38 and in particular the ANTs Cortical Thickness pipeline. atrophy even with a low WM lesion load. 38 Therefore, the segmentation of T2 hyperintensity obtained in step A was used as a mask for the lesion filling of 3D T1. The coregistration of T1 and FLAIR images was operated with a rigid body transformation with ANTs. The mask was then moved onto the 3D T1 image. The lesion filling was operated with the lesion filling routine included in the Lesion Segmentation Tool. 39 The 3D T1 image after lesion filling was then visually evaluated and manually corrected (the lesion-filling step was run a second time with the new manually corrected lesion mask).
Statistical Analysis
For the neuropathological and clinical study, differences among groups were assessed through analysis of variance. Age was used as a correction covariate and post hoc Tukey honest significant difference procedure to account for multiple comparisons. Rank-based nonparametric tests (Kruskal-Wallis and Wilcoxon) were used when the data did not follow a normal distribution (Shapiro test). The Pearson chi-square test was applied to test the difference between groups in terms of male/female ratio, patients with and without IgG oligoclonal bands, and patients with polysymptomatic onset. A false discovery rate (FDR) with a significance level of 0.05 was adopted to correct for the multiple testing problem in the analysis of the CSF protein expression.
To evaluate the specificity and sensitivity of each molecule in predicting high or low cortical damage, different thresholds for each molecule were used to classify patients as MSlow or as MShigh, and for each identified threshold the numbers of true positives and false positives were recorded in a receiver operating characteristic (ROC) curve (Supplementary Table 3 ).
For the multivariate analysis, we utilized as independent variables those cytokines that were consistently raised across both postmortem and in vivo groups and those that were raised in both patient groups and neurofilament protein light levels. Models were run using both cortical lesion number and cortical volume as an outcome using the total population.
Results
Study Cohorts and Subgroup Classification: Postmortem Cohort
Postmortem SPMS cases were stratified according to the degree of meningeal inflammation: the PM-MSlow group (see Table 1 ), with a low density of diffuse meningeal inflammation, and the PM-MShigh group, characterized by a significantly increased degree of meningeal inflammatory infiltration (6.5-fold change, p < 0.0001; see Fig 1) . In particular, a high frequency of immune cell aggregates rich in CD20
1 B cells and CD3 1 T cells was present in the subarachnoid space in the PM-MShigh group (see Table 1 ). The PM-MShigh group was also characterized by a significant increase (2.9-fold, p < 0. (Fig 2A) . A significant increase in the expression of the CXCL9, CXCL10, CXCL13, and TNF genes was found in the meninges of the PM-MShigh group compared to the PM-MSlow group, whereas IL17A gene expression was elevated in the PM-MSlow compared to the PM-MShigh group. Significantly higher protein levels of TNF, LTa, IFNc, CXCL10, CXCL13, CCL17, CCL22, IL2, IL10, IL12p40, and IL16 were found in the CSF of PMMShigh compared to controls, and only IL4 was increased in the CSF of PM-MSlow compared to controls (see Fig 2B) . When the PM-MShigh cases were compared to the PM-MSlow cases, there was a significant increase in the levels of TNF, LTa, CXCL13, CCL22, and IL12p40. In contrast, only IL4 protein was increased in the CSF of PM-MSlow compared with the control group. There was no significant difference in the CSF protein levels of IL17 between the groups (not shown).
Study Populations and Subgroup Classification: In Vivo Patient Population
The demographics and clinical features of the TS population are described in Table 2 . Fifteen patients were classified as TS-MSlow and 20 patients as TS-MShigh on the basis of the number of total cortical lesions (see Materials and Methods). Compared to the TS-MSlow group (Fig  3A) , TS-MShigh patients (see Fig 3B) were characterized by higher cortical lesion load (16.8 6 6.4 vs 0.3 6 0.5, p < 0.0001), higher Expanded Disability Status Scale (2 vs 1.5, p 5 0.017), higher T2WMLV (5.6 6 1.6 vs 4.7 6 1.6, p 5 0.031), and lower mean cortical thickness over the entire brain (2.53 6 0.34 vs 2.72 6 0.41, p 5 0.032).
When the number of merely intracortical lesions (including cortical lesion type II and III) was used to classify the patients, such classification did not change: higher cortical lesion load was found in T-MShigh compared to T-MSlow (7.55 6 3.6 vs 0.2 6 0.4, p < 0.001). 
Higher Cortical Lesion Load at MS Diagnosis Is Associated with Increased Proinflammatory CSF Cytokine and Chemokine Expression
The protein levels of TNF, sTNFR1, IFNc, CXCL12, CXCL13, IL6, IL8, IL10, BAFF, APRIL, LIGHT, TWEAK, MMP-2, pentraxin3, and sCD163 were increased in the CSF of the TS-MShigh group compared to both control and TS-MSlow groups (FDR < 0.05; Fig  4) . Only the protein levels of IFN-a2, IFN-k2, and CCL25 were significantly increased in the TS-MSlow group compared to both control and TS-MShigh groups.
To address the specificity and sensitivity of individual molecules as biomarkers in classifying patients into MSlow and MShigh, we performed ROC curve analysis (see Supplementary Table 3) ; all of these 18 molecules showed a very good classification performance (area under the curve [AUC] 0.80).
Validation of Biomarker Candidates Using an Independent Cohort of MS Patients
The association between CSF NF-L and cortical lesion load found in the TS was validated in the independent VS cohort. An increased NF-L protein expression was also found in VS-MSlow (fold change 5 2.4, p 5 0.049) and VS-MShigh patients (fold change 5 5.4, p < 0.0001) compared to controls, and in VS-MShigh compared to VS-MSlow (fold change 5 2.2, p 5 0.0005; see Fig 3C) . All molecules found to be differentially expressed between TS-MShigh and TS-MSlow were also differentially expressed between the VS-MSlow and VS-MShigh groups in our validation analysis, with the exception of IL6 and TWEAK (see Fig 4) . Specificity, sensitivity and accuracy in classifying cases with a high cortical lesion load and intrathecal inflammation was obtained by ROC analysis of these 18 molecules; except for TWEAK and IL6, all the other molecules showed a good accuracy in classifying cases in this way (AUC 0.70; see Supplementary Table 3 ).
In agreement with the training set results, the classification of the validation set into VS-MSlow and VSMShigh did not change when the intracortical lesions alone were used to classify the patients.
Comparison of the Postmortem and Patient Studies
Among all the molecules analyzed from the postmortem and clinical cohorts, TNF, IFNc, CXCL13, and IL10 were commonly increased in the CSF of PM-MShigh compared to PM-MSlow, TS-MShigh compared to TSMSlow, and VS-MShigh compared to VS-MSlow groups (Fig 5) . In addition, TNF, IFNc, and CXCL13 gene expression was correspondingly found upregulated in the meninges of the PM-MShigh compared to the PMMSlow group. Together, these 3 molecules show a good association (specificity 5 80%, sensitivity 5 100%) with the outcome of VS-MShigh versus VS-MSlow. Moreover, a linear multivariate model was developed (Table 3) containing as independent variables IFNc, TNF, CXCL12, CXCL13, IL6, IL10, and LIGHT, which demonstrates that these variables explain 89% of the variance in , and CCL22 were found in PM-MShigh cases compared to controls. CXCL13, TNF, and CXCL10 gene expression was increased in PM-MShigh compared to PM-MSlow (A), whereas CXCL13, TNF, and CCL22 protein expression was increased in the CSF of PM-MShigh compared to PM-MSlow groups (B). (A) Significantly elevated gene expression for the proinflammatory molecules TNF, IFNc, IL2, IL22, CXCL9, CXCL10, CXCL13, CXCL20, and CCL22 was found in the meninges of the PM-MShigh group compared to controls; IL9 and IL17 gene expression was upregulated in the PM-MSlow group compared to controls; CXCL9, CXCL10, CXCL13, and TNF gene expression was upregulated in the meninges of the PM-MShigh group compared to the PM-MSlow group; finally, IL17A gene expression was elevated in the PMMSlow compared to the PM-MShigh group. (B) Significantly higher protein levels of all the reported molecules in B, except IL4, were found in the CSF of PM-MShigh group compared to controls; only IL4 was increased in the CSF of PM-MSlow compared to controls. When the PM-MShigh cases were compared to the PM-MSlow cases, there was a significant increase in the levels of TNF, LTa, CXCL13, CCL22, and IL12p40. In contrast, only IL4 protein was increased in the CSF of PM-MSlow compared with the control group. Probability values for each statistically significant comparison are reported: *p £ 0.05, **p £ 0.01, ***p £ 0.001. IFN-a2, IFN-k2, IL6, IL8, IL10 , BAFF, APRIL, LIGHT, TWEAK, GM-CSF, MMP-2, pentraxin3, and sCD163 were significantly increased in the CSF of the TS-MShigh and VS-MShigh groups compared to controls (false discovery rate < 0.05). Only the levels of IFN-a2, IFN-k2, and CCL25 were significantly elevated in the MSlow groups compared to both controls and MShigh groups. Significant increases in CXCL12, CXCL13, IFNc, TNF, TNFR1, APRIL, LIGHT, and BAFF were also observed in the CSF of TS-MShigh and VS-MShigh compared to TS-MSlow and VS-MSlow groups, respectively. Statistical analysis of the data was performed using the nonparametric Mann-Whitney test. Probability values for each statistically significant comparison are reported: *p £ 0.05, **p £ 0.01, ***p £ 0.001. cortical lesion volume (n 5 39, R 2 5 0.8856, p < 0.0001) and 87% of the variance in cortical lesion number (n 5 39, R 2 5 0.876, p < 0.0001). There were no significant variables that could predict T2WMLV (data not shown). Furthermore, we found that the 3 cytokines that were elevated in the postmortem meninges and CSF and in both patient groups, namely TNF, IFNc, and CXCL13, explained in turn 88% (0.7824/0.8856) of the variance explained by the 7-cytokine model for cortical lesion number (Fig 6A) and 86% (0.7511/0.8752) of the variance for cortical lesion volume (see Fig 6B) .
Discussion
We have identified an intrathecal (meninges and CSF) inflammation profile in a postmortem MS cohort that is defined by high levels of GM demyelination and meningeal inflammation. The molecular pattern of increased CSF proinflammatory cytokines and chemokines (TNF, LTa, IFNc, IL2, IL10, IL12p40, IL16, CXCL10, CXCL13, CXCL20, CCL17, and CCL22) was associated with increased meningeal inflammation and GM demyelination and, in addition, early disability onset and age at death. The finding of increased intrathecal levels of molecules associated with B-cell recruitment and activity (CXCL13, CXCL10, IL6, IL10, TNF, and LTa), together with their increased gene expression, in the subgroup of postmortem MS patients with high meningeal inflammation and cortical GM demyelination, strongly suggests a link between the degree of the compartmentalized meningeal immune response and both the underlying cortical pathology and a more rapid disease evolution. The lack of tight junctions in cells lining the pial membrane, damage to the glia limitans caused by the inflammation, 5 and a degree of continuity between the subarachnoid and perivenular spaces would allow proteins derived from circulating CSF to easily reach the underlying GM. 40 Due to the similarity between the changes in mRNA levels in the meninges and protein levels in the CSF, we suggest that immune cells in the subarachnoid space, whether diffuse or focally organized, release inflammatory/cytotoxic mediators into the CSF, creating a intracerebral milieu that sustains chronic compartmentalized inflammation and, at the same time, directly mediates and/or exacerbates cortical pathology and disease progression. 40 It was not possible to include in our study postmortem CSF samples from cases of non-MS CNS inflammatory conditions, so we cannot say at this stage that the clear association between the particular combination of cytokines and chemokines and the underlying cortical pathology is specific to MS. To determine whether the postmortem CSF profiles are present at earlier stages in the disease process, we analyzed the intrathecal immune profile associated with increased cortical pathology at the time of diagnosis of 2 independent groups of MS patients. The groups of MS patients with increased GM damage on MRI showed a remarkably similar, but not identical, CSF profile when compared to the postmortem samples with increased GM demyelination, even at this early stage of disease. This is in agreement with the observation of substantial meningeal infiltrates and subpial demyelination in cortical biopsies of patients at the early stages of disease.
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Even the protein levels in vivo were quantitatively similar to those observed in the postmortem samples. In particular, a combination of proinflammatory cytokines (TNF, IFNc, IL6) and molecules involved in lymphoid neogenesis (CXCL12, CXCL13, TNF) and B-cell and plasma cell/blast activity (IL6, IL10, TNF, BAFF, APRIL, LIGHT, TWEAK) defined those subjects with the most extensive GM demyelination. The further analysis of CSF from an independent unbiased cohort of MS patients with an heterogeneous degree of disease severity, who were consecutively enrolled in the neurology clinic at the time of diagnosis, identified an almost identical cytokine/chemokine profile, thus validating and increasing confidence in our findings. The elevated CSF expression of major inflammatory molecules, such as TNF, IFNc, BAFF, IL6, and IL8, suggests the presence of an elevated involvement of multiple immune cell populations, including T lymphocytes and monocytes, indicating an increased inflammatory activity that probably characterizes patients with increased cortical pathology and a more progressive clinical disease. In addition, the different immune populations contributing to the intracerebral inflammatory activity might also have an important role in the activation and regulation of the B-cell and plasma blast functions.
In contrast, although less well defined, a different inflammatory profile associated with innate and myeloid immunity (type I and III IFNs) and Th2 regulatory molecules (CCL25) was observed in the CSF of MS patients with low GM lesion number and volume. This suggests that the balance of inflammatory mechanisms in this patient group is altered toward the downregulation of proinflammatory pathways. In this context, the increase in gene expression for IL17 in the postmortem meninges of MS cases with only low levels of inflammation and demyelination was somewhat surprising given its role in promoting meningeal inflammation in mice 41 and points toward a possible immunoregulatory role in this compartment in progressive MS. However, no significant difference was seen in the levels of IL17 protein in the postmortem CSF and it was not included in the multiplex analysis of the patient samples. Further investigations are thus required to understand the role of IL17 in progressive disease. It is intriguing that such a CSF profile includes high levels of molecules linked to B-cell recruitment and maintenance in the CNS (CXCL13 and CXCL12) as well as mediators related to B-cell immune functions (IL6, IL10, TNF, BAFF, APRIL, TWEAK) at this early stage of the disease evolution. This supports a key role for a compartmentalized B-cell and plasma cell/blast response in the pathogenesis of GM damage at least in a subgroup of patients from an early stage. 16, 42, 43 Such data reinforce the idea that the immune response is compartmentalized and may help to explain why most of the immunomodulatory drugs are ineffective in progressive MS, 44, 45 as they do not efficiently access this compartment. Our observations are also in line with previous studies 6, 15, 28, 42, 46, 47 and confirm the key role of a compartmentalized adaptive immune response that specifically mediates and exacerbates the pathology of the adjacent cerebral cortex in MS. The finding of specific individual CSF/MRI profiles linked to the degree of meningeal inflammation and cortical lesion load at the time of the diagnosis suggests that a specific differential involvement of intrathecal inflammatory responses, possibly compartmentalized in ectopic lymphoidlike structures, and of GM demyelination might be linked to long-term disease evolution.
To confirm that the patients with a higher cortical lesion load on MRI (TS-MShigh) are characterized by more severe GM damage, we have also evaluated the global cortical thickness (a general proxy of GM atrophy) and the levels of NF-L in the CSF. Both of these parameters clearly suggest that the inflammatory and neurodegenerative processes within the GM are significantly more aggressive in patients with a higher cortical lesion load, as previously suggested by a number of imaging studies. 9 They also confirm previous neuropathological findings of increased axonal and neuronal loss in subpial GM lesions of MS patients with increased levels of meningeal inflammation and more rapid disease progression, 5, 6, 16, 17 suggesting that an intrathecal inflammatory milieu may be a key determinant of the rate of cortical neurodegeneration in MS.
The combined postmortem and patient results suggest that cortical damage in MS is associated with a specific inflammatory intrathecal profile that is already detectable at disease onset, persists throughout the entire disease course, and can be still detected at the final stage of the disease in the postmortem brain, although further longitudinal studies are necessary to substantiate this idea. Moreover, these data point out the crucial value of the CSF analysis, suggesting that it might be possible to identify MS patients at high risk of severe GM damage already at the point of diagnosis by a specific combined CSF and MRI profile. Finally, the association of both severe GM damage and meningeal inflammation with a more rapidly progressing disease, as observed by several imaging 8 and postmortem studies, 6,11,15,16 also confirms the possible prognostic value of such data and the possibility of stratifying patients for more appropriate treatment options already at diagnosis. In particular, the panel of molecules commonly identified in both the neuropathological and clinical arms of the study (CXCL13, IL10, TNF, and IFNc) might represent a useful prognostic signature of cortical damage and meningeal inflammation, linked to a more rapid and severe disease progression. The classification into 2 MS subgroups with substantially different cortical lesion load at diagnosis was also confirmed when only intracortical lesions alone were used to classify the patients. This strongly supports the existence of a "cortical variant" of MS in which the cerebral cortex is predominantly or exclusively involved. 48 Although 4 different experiments have been conducted to increase the reliability of our data, this study is not without limitations. We see the low sensitivity of MRI methodologies in detecting all cortical lesions in vivo to be a limitation, although comparative neuropathological and in vivo studies have suggested that the load of detectable MRI cortical lesions is well correlated with the total number of cortical lesions observed by neuropathological assessments, including the most numerous subpial type III cortical lesions. 49, 50 Nevertheless, to overcome this limitation and to identify patients with a more severe cortical pathology, we also included in our analysis a reliable evaluation of cortical thickness and of CSF NF-L as additional markers of GM damage. Moreover, we have analyzed postmortem tissues applying the same criteria (cases are differentiated according to cortical lesion load) used for the MS patients. As the examined postmortem MS population was made up of SPMS cases, the level of cortical demyelination is of course substantially more severe than that detected in RRMS patients at diagnosis by 3T MRI methodology. However, such a combined analysis as used in this study still suggests that it may be possible to stratify MS patients according to the GM lesion load and inflammatory profile at any disease stage. A further limitation of this study may be the stringent biostatistical analyses performed, which might have underestimated the number of significant biomarkers. Extending this study to a larger MS population could help to identify a more complex and complete panel of CSF biomarkers associated with cortical damage and intrathecal inflammation. Finally, the lack of a clinical follow-up at this stage has necessitated the use of several surrogate markers of disease severity to indicate the development of early and severe GM damage. Therefore, longitudinal studies are required to confirm, in vivo, that the CSF profile associated with severe GM damage can be used as a prognostic marker of disease evolution.
In conclusion, our analysis has identified a set of inflammatory mediators in patient CSF captured at diagnosis that reflects the state of meningeal inflammation and the extent of cortical damage, which is comparable to that seen postmortem in neuropathologically characterized MS. The similarity of such a CSF profile with that observed at death in more rapidly progressive MS cases strongly reinforces a potential key role of CSF analysis at disease onset and indicates its possible utility as a prognostic marker for MS course from the early phase of the disease. Because modern advanced imaging techniques are not yet able to specifically identify and quantify meningeal inflammation 14 and subpial demyelination, we propose the combined CSF and MRI profiling of the MS patients at diagnosis will be an appropriate in vivo surrogate of meningeal and intrathecal inflammation and might help to define other different specific MS phenotypes related to the characteristic heterogeneity of the disease and subsequently to select the most appropriate treatment.
